Shared Decision-Making in Hematologic Malignancies

Video
Conference|National Comprehensive Cancer Network Annual Meeting (NCCN)

In this video we discuss the goals of shared-decision making in hematologic malignancies and touch upon different scenarios where its use may be appropriate.

In this video, Thomas W. LeBlanc, MD, MA, of the Duke Cancer Institute in Durham, North Carolina, discusses the goals of shared-decision making when treating patients with hematologic malignancies and touches upon different scenarios where its use may be appropriate.

Dr. LeBlanc gave a presentation on this topic at the 11th Annual National Comprehensive Cancer Network (NCCN) Hematologic Malignancies Congress, held September 1–October 1 in New York.

Recent Videos
Future meetings may address how immunotherapy, bispecific agents, and CAR T-cell therapies can further impact the AML treatment paradigm.
Treatment with revumenib appeared to demonstrate efficacy among patients with KMT2A-rearranged acute leukemia in the phase 2 AUGMENT-101 study.
Advocacy groups such as Cancer Support Community and the Leukemia & Lymphoma Society may help support patients with CML undergoing treatment.
Data from the REVEAL study affirm elevated white blood cell counts and higher variant allele frequency as risk factors for progression in polycythemia vera.
Additional analyses of patient-reported outcomes and MRD status in the QuANTUM-First trial are also ongoing, says Harry P. Erba, MD, PhD.
Investigators must continue to explore the space for lisocabtagene maraleucel in mantle cell lymphoma, according to Manali Kamdar, MD.
Those with CML should discuss adverse effects such as nausea or fatigue with their providers to help optimize their quality of life during treatment.
Patients with CML can become an active part of their treatment plan by discussing any questions that come to mind with their providers.
Jorge E. Cortes, MD, emphasizes proper communication between patients with chronic myeloid leukemia and their providers during the treatment course.
Dietary interventions or other medications may help mitigate diarrhea in patients who undergo therapy for chronic myeloid leukemia.
Related Content
Following rare CRS and ICANS incidence following CAR T-cell therapy, investigators propose a reduced 2-week monitoring period with extensions as needed.

Flexible Monitoring for CAR T-Cell Therapy May Improve Treatment Access

Roman Fabbricatore
July 24th 2024
Article

Following rare CRS and ICANS incidence following CAR T-cell therapy, investigators propose a reduced 2-week monitoring period with extensions as needed.

Experts discuss updated findings presented at the 2024 EHA Congress in diseases such as mantle cell lymphoma and acute myeloid leukemia.

Ensuring Quality Outcomes in Hematologic Cancer Subgroups at EHA 2024

Manali Kamdar, MD;Michael Grunwald, MD;Harry P. Erba, MD, PhD
June 24th 2024
Podcast

Experts discuss updated findings presented at the 2024 EHA Congress in diseases such as mantle cell lymphoma and acute myeloid leukemia.

Mesenchymal stromal cells with chimeric antigen receptors for enhanced immunosuppression

Mesenchymal stromal cells with chimeric antigen receptors for enhanced immunosuppression

American Society for Transplantation and Cellular Therapy
July 1st 2024
Article

Researchers at the Mayo Clinic have found that mesenchymal stromal cells engineered with chimeric antigen receptors can enhance immunosuppression in the context of immune-related disorders.

Oncology Peer Review On-The-Go: Minority Treatment Disparities and Clinical Trial Enrollment

Oncology Peer Review On-The-Go: Minority Treatment Disparities and Clinical Trial Enrollment

Matthew Fowler
July 6th 2020
Podcast

The first episode of CancerNetwork's podcast Oncology Peer Review On-The-Go explores disparities in cancer care treatment among minorities and the significance of a representative sample in clinical trials.

Frontline acalabrutinib plus bendamustine/rituximab may become a new standard therapy in MCL, according to Michael Wang, MD.

Acalabrutnib Combo Shows PFS Benefit in Elderly MCL Population

Gina Mauro
June 27th 2024
Article

Frontline acalabrutinib plus bendamustine/rituximab may become a new standard therapy in MCL, according to Michael Wang, MD.

Approved for use in newly diagnosed and previously treated myelofibrosis, momelotinib may addresses key manifestations of the disease.

Momelotinib Receives Japanese Approval for Treatment of Myelofibrosis

Roman Fabbricatore
June 24th 2024
Article

Approved for use in newly diagnosed and previously treated myelofibrosis, momelotinib may addresses key manifestations of the disease.